New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 24, 2014
07:12 EDTBAYRY, EVGNEvogene announces amendment to Bayer wheat agreement
Evogene (EVGN) announced an amendment to the remaining work plan under its collaboration with Bayer CropScience LP (BAYRY) for improved wheat. Pursuant to the amended work plan, Evogene will shift from discovery of additional genes and SNP’s to discovery of novel genomic promoters. Under the amended agreement, Evogene will continue in close teamwork with Bayer to utilize its ATHLETE discovery platform but will shift the focus from the discovery of additional genes and SNP's to identifying novel genomic promoters.
News For EVGN;BAYRY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
08:36 EDTBAYRYZoetis guidance positive, says BMO Capital
Subscribe for More Information
November 18, 2014
05:43 EDTBAYRYRegeneron announces EYLEA injection approved for DME treatment in Japan
Subscribe for More Information
November 14, 2014
07:14 EDTBAYRYAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
November 13, 2014
09:33 EDTBAYRYZoetis could get bought by Bayer for $53/share, says Jefferies
Subscribe for More Information
November 12, 2014
08:18 EDTBAYRYUBS to hold a conference
Subscribe for More Information
06:22 EDTBAYRYZoetis price target raised to $49 from $44 at Citigroup
Citigroup raised its price target for Zoetis (ZTS) shares to $49 after activist Pershing Square confirmed the accumulation of a 10% stake in the company. Citi thinks Pershing is interested in advocating for a sale of Zoetis, potentially to Valeant (VRX) if its bid for Allergan (AGN) fails. Citi believes others, including Bayer (BAYRY), could be interested in acquiring Zoetis. It keeps a Buy rating on the stock.
November 10, 2014
16:07 EDTBAYRYUBS to hold a conference
UBS European Conference is being held in London, England on November 11-12.
07:24 EDTEVGNEvogene reports Q3 EPS (12c), consensus (11c)
Reports Q3 revenue $3.16M, consensus $4.21M

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use